|Adjusted for Framingham Risk Score∗||Adjusted for Maximum Wall Thickness∗||Adjusted for AIM-HIGH Treatment Arm∗|
|HR†||95% CI||p Value||HR†||95% CI||p Value||HR†||95% CI||p Value|
|LRNC volume, mm3||1.42||1.15–1.74||0.001||1.58||1.06–2.35||0.02||1.44||1.17–1.77||<0.001|
|LRNC volume, %||1.56||1.14–2.13||0.005||1.99||1.06–3.73||0.03||1.62||1.21–2.16||0.001|
|Calcification volume, mm3||0.58||0.24–1.40||0.20||0.45||0.18–1.15||0.10||0.60||0.26–1.39||0.20|
|Calcification volume, %||0.65||0.33–1.26||0.20||0.53||0.27–1.06||0.07||0.67||0.35–1.27||0.20|
|Thin/ruptured fibrous cap||4.18||1.57–11.14||0.004||4.04||1.23–13.22||0.02||4.61||1.77–11.98||0.002|
|AHA type VI‡||2.33||0.74–7.31||0.15||1.47||0.35–6.12||0.60||2.51||0.82–7.68||0.11|
Abbreviations as in Table 1.
↵∗ All models are bivariate, with 1 plaque characteristic variable and a single adjustment variable. Adjustment was made individually for the Framingham risk score for recurrent events in patients with coronary heart disease or stroke (29), maximum wall thickness, and treatment assignment in AIM-HIGH.
↵† For continuous variables, hazard ratios are presented per 1 SD increase.
↵‡ AHA type VI lesions include plaques with surface disruption (i.e., cap rupture, ulceration, and calcified nodule), intraplaque hemorrhage, or mural thrombus.
↵§ CAS-4 lesions include AHA type VI lesions as well as those with maximum percent LRNC area (LRNC area/wall area) >40%.